Study guide
4.2 Cardiovascular Disorders & Management
ANCC Medical-Surgical Nursing Certification MEDSURG-BC
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current Exam Facts: Format, Scoring, Cost 1.2 Eligibility, Application & Scheduling 1.3 Blueprint Breakdown & Study Strategy 1.4 Test-Taking Strategies for ANCC Scenario Items
2 Assessment Skills
2.1 Health History Collection 2.2 Physical Assessment 2.3 Psychosocial Assessment 2.4 Cognitive & Neurological Screening
3 Diagnostics & Clinical Reasoning
3.1 Diagnostic & Laboratory Testing 3.2 Fluids & Electrolytes 3.3 Nursing Diagnosis Identification & Prioritization
4 Cardiovascular & Hematologic
4.1 Cardiovascular Assessment & Diagnostics 4.2 Cardiovascular Disorders & Management 4.3 Hematologic Disorders & Blood Products
5 Respiratory
5.1 Respiratory Assessment & Diagnostics 5.2 Respiratory Disorders & Management 5.3 Oxygen Therapy & Ventilation Support
6 Gastrointestinal & Renal
6.1 GI Assessment & Common Disorders 6.2 GI Management & Nutrition Support 6.3 Renal & Urinary Assessment & Disorders 6.4 Acute Kidney Injury & Renal Replacement Therapies
7 Neurologic & Musculoskeletal
7.1 Neurologic Assessment & Stroke 7.2 Neurologic Disorders & Management 7.3 Musculoskeletal Assessment & Disorders 7.4 Orthopedic Care, Immobilization & Mobility
8 Endocrine, Integumentary & Immune
8.1 Endocrine Assessment & Diabetes Management 8.2 Thyroid, Adrenal & Metabolic Disorders 8.3 Integumentary Disorders & Wound Care 8.4 Immune, Infectious & Multisystem Conditions
9 Care Planning & Education
9.1 Nursing Care Planning 9.2 Patient Teaching: Process & Evaluation 9.3 Education Topics & Self-Management 9.4 Health & Wellness Promotion
10 Perioperative Care
10.1 Preoperative & Intraoperative Care 10.2 Postoperative Complication Prevention 10.3 Postoperative Emergencies: Bleeding, Infection, Emboli
11 Patient Safety
11.1 Patient Safety: Falls, Restraints & Equipment 11.2 Infection Prevention & Isolation Precautions 11.3 Recognizing Deterioration & Escalation of Care
12 Pharmacology
12.1 Safe Medication Administration 12.2 Interactions & Adverse Effects 12.3 Pain Management & Analgesics 12.4 Polypharmacy & High-Alert Medications
13 Non-Pharmacologic & Comfort Care
13.1 Non-Pharmacologic Treatments & CAM 13.2 Comfort & End-of-Life Care
14 Therapeutic Communication
14.1 Therapeutic Communication 14.2 Cultural Competence & Family-Centered Care 14.3 Difficult Conversations & Counseling
15 Interprofessional Collaboration
15.1 Interdisciplinary Team Collaboration 15.2 Delegation & Supervision 15.3 Care Coordination, Consults & Transitions
16 Ethics & Evidence-Based Practice
16.1 Nursing Ethics & Patient Advocacy 16.2 Legal & Regulatory Foundations 16.3 Evidence-Based Practice & Research 16.4 Quality Improvement & Safety Culture
4.2 Cardiovascular Disorders & Management
Key Takeaways Explain This Topic AI
Report a daily weight gain of 2-3 lb in 24 hours or 5 lb in one week; typical fluid restriction in advanced heart failure is 1.5-2 L/day with about 2 g/day sodium
A 36-hour ACE-inhibitor washout is required before starting sacubitril/valsartan (ARNI) to prevent life-threatening angioedema
Digoxin therapeutic level is 0.5-2.0 ng/mL; hypokalemia potentiates toxicity, which presents with anorexia, nausea, bradycardia, and yellow-green visual halos
STEMI reperfusion goals: door-to-balloon within 90 minutes and door-to-fibrinolytic within 30 minutes; give oxygen only if SpO2 is below 90%
Defibrillate (unsynchronized) VF and pulseless VT; use synchronized cardioversion for unstable tachycardia WITH a pulse; position PAD legs dependent but elevate legs in venous disease
Last updated: August 2026
Heart Failure
Heart failure (HF) is the heart's inability to pump enough blood to meet metabolic demands. Classify it by ejection fraction:
- HFrEF (reduced EF, 40% or less) — systolic failure; the ventricle cannot contract effectively
- HFpEF (preserved EF, 50% or more) — diastolic failure; the ventricle is stiff and cannot fill
- HFmrEF — mildly reduced EF, 41-49%
- NYHA Functional Classification
- Class Description
- I No limitation of ordinary activity
- II Slight limitation; comfortable at rest, symptoms with ordinary activity
- III Marked limitation; symptoms with minimal activity
- IV Symptoms at rest; unable to perform any activity without discomfort
- Monitoring and Self-Care Teaching
Daily weight : same time, same scale, similar clothing, after voiding. Report a gain of 2-3 lb in 24 hours or 5 lb in a week
Fluid restriction of 1.5-2 L/day is typical for advanced or hyponatremic HF; restrict sodium to about 2 g/day
Left-sided failure produces pulmonary symptoms: dyspnea, orthopnea, crackles, S3, and pink frothy sputum. Right-sided failure produces systemic congestion: JVD, peripheral edema, hepatomegaly, and ascites
Key Drug Classes
ACE inhibitors (lisinopril) and ARBs (losartan): reduce afterload and ventricular remodeling; monitor potassium and creatinine. A dry cough is common with ACE inhibitors; angioedema is a stop-the-drug emergency
ARNI (sacubitril/valsartan): requires a 36-hour washout after the last ACE-inhibitor dose to prevent angioedema
Beta blockers (metoprolol succinate, carvedilol): start low and titrate up; hold for bradycardia or hypotension; never stop abruptly (rebound tachycardia and ischemia)
- Loop diuretics (furosemide): monitor potassium; rapid IV push can cause ototoxicity
- Spironolactone : potassium-sparing aldosterone antagonist; watch for hyperkalemia and gynecomastia
- SGLT2 inhibitors (dapagliflozin, empagliflozin): reduce HF hospitalizations even in patients without diabetes
Digoxin : therapeutic level 0.5-2.0 ng/mL . Toxicity (above 2.0) causes anorexia, nausea, vomiting, bradycardia, and yellow-green visual halos ; hypokalemia potentiates toxicity even at normal levels. Take an apical pulse for a full minute and hold the dose if below 60 beats/min. The antidote for severe toxicity is digoxin immune Fab
Acute Coronary Syndrome
ACS spans unstable angina (no troponin rise), NSTEMI (elevated troponin without persistent ST elevation), and STEMI (ST elevation of 1 mm or more in two contiguous leads from total coronary occlusion). Reperfusion timelines: door-to-balloon (PCI) within 90 minutes ; door-to-fibrinolytic (needle) within 30 minutes . Time is muscle.
The classic MONA mnemonic has been updated: morphine is reserved for refractory pain (not routine); oxygen only if SpO2 is below 90% ; nitroglycerin 0.4 mg sublingual every 5 minutes for up to 3 doses — hold if systolic BP is under 90 mm Hg, if a phosphodiesterase inhibitor (sildenafil, tadalafil) was used in the last 24-48 hours, or if right ventricular infarction is suspected; aspirin 162-325 mg chewed (non-enteric) remains first-line.
Dysrhythmias
Atrial fibrillation : irregularly irregular rhythm with no P waves. Goals are rate control (metoprolol, diltiazem) and stroke prevention with anticoagulation guided by the CHA2DS2-VASc score. If duration exceeds 48 hours or is unknown, provide therapeutic anticoagulation for about 3 weeks (or confirm no thrombus with TEE) before cardioversion, and continue anticoagulation at least 4 weeks after
First-degree AV block : constant PR interval above 0.20 s; usually monitor only
Second-degree Mobitz I (Wenckebach) : PR progressively lengthens until a beat is dropped; atropine if symptomatic
Second-degree Mobitz II : dropped QRS complexes without PR lengthening; high risk of progressing to complete block — prepare for a pacemaker
Third-degree (complete) heart block : AV dissociation; atropine is often ineffective — use transcutaneous then transvenous pacing
Ventricular fibrillation and pulseless ventricular tachycardia : shockable rhythms — immediate CPR, unsynchronized defibrillation , and epinephrine 1 mg IV every 3-5 minutes
Asystole and PEA : NOT shockable — CPR and epinephrine while searching for reversible causes (the Hs and Ts)
Tachycardia with a pulse : vagal maneuvers and adenosine for stable SVT; synchronized cardioversion for unstable patients who still have a pulse. Never cardiovert a pulseless patient — defibrillate instead
Hypertension
ACC/AHA thresholds: normal is below 120/80 mm Hg; elevated is 120-129 with diastolic under 80; Stage 1 is 130-139 or 80-89; Stage 2 is 140 or higher, or 90 or higher. Confirm readings with proper technique: seated with back supported, feet flat, correct cuff size, arm at heart level, and no caffeine or smoking within 30 minutes.
Hypertensive urgency : severe elevation (often 180/120 mm Hg or higher) without acute target-organ damage; treat with oral agents and lower pressure gradually over 24-48 hours
Hypertensive emergency : severe elevation with acute target-organ damage (encephalopathy, aortic dissection, pulmonary edema, eclampsia, acute MI); admit to the ICU and use IV agents ( nicardipine, labetalol, nitroprusside ). Reduce mean arterial pressure by no more than 20-25% in the first hour — faster drops risk ischemic stroke and coronary hypoperfusion
Peripheral Arterial vs Venous Disease
- Feature Arterial (PAD) Venous (CVD)
- Pain Intermittent claudication , rest pain Aching, heaviness, cramping
- Pulses Diminished or absent Present
- Skin Cool, shiny, hairless; pallor on elevation, dependent rubor Warm, brown hemosiderin staining
- Edema Minimal Moderate to marked
Ulcers Painful, round, well-demarcated; toes and pressure points Mildly painful, irregular borders; medial malleolus
Positioning Dependent/dangle — do NOT elevate Elevate the legs; compression therapy
Teach patients with PAD to follow structured walking programs, stop smoking, practice meticulous foot care, and avoid crossing the legs or wearing constrictive clothing.
Clinical Pearls
Store nitroglycerin in its dark glass bottle, expect a tingling or burning sensation under the tongue, and replace the supply about every 6 months
Teach patients on digoxin to report visual changes, nausea, or a slow pulse before taking the next dose
Never massage a swollen, tender calf — if the cause is a deep vein thrombosis , massage can dislodge the clot and cause a pulmonary embolism